Abstract: 【Abstract】 Objective We examined serum calcium, phosphate, intact parathyroid hormone and 1,25(OH)2-D3 as well as serum fibroblast growth factor 23 (FGF-23), and investigated whether these factors influence serum FGF-23 in maintenance (MHD) hemodialysis patients. Methods We recruited 98 MHD patients and 28 controls with normal renal function in this study. Their serum alkaline phosphatase, calcium, phosphate and intact parathyroid hormone were determined, and their serum 1,25(OH)2-D3 and FGF-23 were measured by ELISA. We then divided the MHD patients into 3 groups: hypophosphatemia group, normal serum phosphate group and hyperphosphatemia group. Results In MHD patients, serum 1,25(OH)2-D3 was lower than that of control group (P <0.001), but FGF-23 was significantly higher that of control group (P <0.001). Serum FGF-23 had no significant differences among hypophosphatemia group, normal serum phosphate group and hyperphosphatemia group (P = 0.804). Multiple linear regression analysis revealed that serum 1,25(OH)2-D3 was the factor that influences serum FGF-23 in MHD patients (r =0.481, P <0.001). Conclusions In MHD patients, serum FGF-23 increases significantly, and serum 1,25(OH)2-D3 is the factor relating to the increase of serum FGF-23. However, serum phosphate seems to have no impact on the increase of serum FGF-23 in MHD patients.

Key words: 25(OH)₂-D₃, Fibroblast growth factor 23